COVID-19 Archives - Page 2 of 16

Feature

Claritas Pharmaceuticals transforming nitric oxide therapy

Claritas Pharmaceuticals (TSXV:CLAS; OTC:CLAZF) is developing R-107, a liquid drug candidate that may hold the key to transforming nitric oxide therapy from its current gaseous inhalation method of delivery to...

April 26, 2022

Developments

FDA rejects Ampio Pharma proposal for modified filing of Ampion

The FDA rejected Ampio Pharmaceuticals’ (NYSE American:AMPE) proposed modified intent-to-treat (mITT) population as the primary analysis population for evaluating efficacy in the AP-013 trial, and the acceptability of...

April 21, 2022

Feature

In conversation with Dr. Murat Kalayoglu of Cartesian

As president and CEO of closely-held Cartesian Therapeutics, Murat Kalayoglu, M.D., Ph.D., has made a smooth transition over the years from a board-certified ophthalmologist to a healthcare IT entrepreneur to a medical...

April 12, 2022

Developments

Altamira data in SARS-CoV-2 Delta variant with Bentrio published in IJMS

The International Journal of Molecular Sciences (IJMS) published a peer-reviewed paper confirming Altamira Therapeutics’ (NASDAQ:CYTO) positive research findings regarding the in vitro efficacy and safety of its drug...

April 11, 2022

Markets

Cantor assumes coverage of SI-BONE at OW; PT $34 down from $41

Cantor Fitzgerald analyst Ross Osborn assumed coverage of SI-BONE (NASDAQ:SIBN) with an “overweight” rating and price target of $34. The stock closed at $21.28 April 6. SI-BONE is a medical device company that...

April 7, 2022

Feature

Cocrystal Pharma advancing programs in high-value antiviral drug targets

With a drug discovery technology platform developed by several Nobel Prize laureates, Cocrystal Pharma (NASDAQ:COCP) is advancing broad spectrum antivirals in three programs: coronaviruses and variants, pandemic and...

April 5, 2022

Executive Moves

RNA Disease Diagnostics adds chief scientific advisor, president to board

Dipanjan Pan RNA Disease Diagnostics (RNADD) appointed its chief scientific advisor, Prof. Dipanjan Pan, Ph.D., and company president, John Erickson, Jr., to the board to further position RNADD to execute the next...

April 4, 2022

Executive Moves

Long-time research analyst Anthony Petrone joins Mizuho Americas

Anthony Petrone Mizuho Americas hired Anthony Petrone as a managing director, senior medical devices, diagnostics and therapeutics equity research analyst. Mr. Petrone has more than 16 years of experience in...

March 28, 2022

Feature

First Wave developing targeted, non-systemic therapies for GI diseases

First Wave BioPharma (NASDAQ:FWBI) is advancing multiple clinical-stage programs built around its two proprietary technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and a...

March 22, 2022

Markets

BTIG cuts Talis Biomedical to sell; PT $1

BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “sell” from “neutral” with a price target of $1, citing a delay in the beta-phase rollout of the Talis One COVID-19 diagnostic, which was planned for the first quarter...

March 18, 2022

Tag - COVID-19

Claritas Pharmaceuticals transforming nitric oxide therapy

FDA rejects Ampio Pharma proposal for modified filing of Ampion

In conversation with Dr. Murat Kalayoglu of Cartesian

Altamira data in SARS-CoV-2 Delta variant with Bentrio published in IJMS

Cantor assumes coverage of SI-BONE at OW; PT $34 down from $41

Cocrystal Pharma advancing programs in high-value antiviral drug targets

RNA Disease Diagnostics adds chief scientific advisor, president to board

Long-time research analyst Anthony Petrone joins Mizuho Americas

First Wave developing targeted, non-systemic therapies for GI diseases

BTIG cuts Talis Biomedical to sell; PT $1

General

More